Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
- 1 May 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Pharmacogenomics
- Vol. 18 (7), 701-739
- https://doi.org/10.2217/pgs-2017-0194
Abstract
Currently, most guidelines on drug–drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug–gene interaction (DGI) where there are multiple biotransformation pathways, which is referred to as drug–drug–gene interaction (DDGI). In this systematic review, we report the impact of pharmacogenetics on DDI and DDGI in which three major drug-metabolizing enzymes – CYP2C9, CYP2C19 and CYP2D6 – are central. We observed that several DDI and DDGI are highly gene-dependent, leading to a different magnitude of interaction. Precision drug therapy should take pharmacogenetics into account when drug interactions in clinical practice are expected.Keywords
This publication has 133 references indexed in Scilit:
- Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy VolunteersClinical Pharmacology & Therapeutics, 2012
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamineEuropean Journal of Clinical Pharmacology, 2011
- Perpetrators of pharmacokinetic drug–drug interactions arising from altered cytochrome P450 activity: a criteria‐based assessmentBritish Journal of Clinical Pharmacology, 2011
- Influences of different proton pump inhibitors on the anti‐platelet function of clopidogrel in relation to CYP2C19 genotypesBritish Journal of Clinical Pharmacology, 2010
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Gefitinib–phenytoin interaction is not correlated with the 14C‐erythromycin breath test in healthy male volunteersBritish Journal of Clinical Pharmacology, 2009
- Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjectsBritish Journal of Clinical Pharmacology, 2008
- Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemiaBritish Journal of Clinical Pharmacology, 2008
- Differential Genotype Dependent Inhibition of CYP2C9 in HumansDrug Metabolism and Disposition, 2008